Declared Dividend • Jul 06
Dividend of CN¥0.58 announced Shareholders will receive a dividend of CN¥0.58. Ex-date: 8th July 2026 Payment date: 8th July 2026 Dividend yield will be 2.5%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (81% earnings payout ratio) but not covered by cash flows (241% cash payout ratio). The dividend has increased by an average of 8.4% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 27% over the next year, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Jul 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥34.68, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 20% over the past three years. New Risk • Jul 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (241% cash payout ratio). Share price has been volatile over the past 3 months (8.8% average weekly change). Announcement • Jun 30
Chison Medical Technologies Co., Ltd. to Report First Half, 2026 Results on Aug 28, 2026 Chison Medical Technologies Co., Ltd. announced that they will report first half, 2026 results on Aug 28, 2026 Buy Or Sell Opportunity • May 25
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to CN¥38.36. The fair value is estimated to be CN¥29.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 3.1%. Revenue is forecast to grow by 37% in a year. Earnings are forecast to grow by 51% in the next year. Reported Earnings • Apr 21
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥1.04 (down from CN¥1.26 in FY 2024). Revenue: CN¥435.8m (down 7.0% from FY 2024). Net income: CN¥116.5m (down 17% from FY 2024). Profit margin: 27% (down from 30% in FY 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Announcement • Apr 20
Chison Medical Technologies Co., Ltd., Annual General Meeting, May 11, 2026 Chison Medical Technologies Co., Ltd., Annual General Meeting, May 11, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Wuxi, Jiangsu China Announcement • Mar 30
Chison Medical Technologies Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Chison Medical Technologies Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Reported Earnings • Mar 01
Full year 2025 earnings released: EPS: CN¥1.04 (vs CN¥1.26 in FY 2024) Full year 2025 results: EPS: CN¥1.04 (down from CN¥1.26 in FY 2024). Revenue: CN¥447.3m (down 4.6% from FY 2024). Net income: CN¥116.6m (down 17% from FY 2024). Profit margin: 26% (down from 30% in FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 1% per year. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥35.45, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 26x in the Medical Equipment industry in China. Total loss to shareholders of 1.2% over the past three years. Buy Or Sell Opportunity • Jan 05
Now 24% overvalued Over the last 90 days, the stock has fallen 2.5% to CN¥32.08. The fair value is estimated to be CN¥25.78, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 44% in the next 2 years. Announcement • Dec 26
Chison Medical Technologies Co., Ltd. to Report Fiscal Year 2025 Results on Apr 20, 2026 Chison Medical Technologies Co., Ltd. announced that they will report fiscal year 2025 results on Apr 20, 2026 Reported Earnings • Oct 22
Third quarter 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.15 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.22 (up from CN¥0.15 in 3Q 2024). Revenue: CN¥107.0m (down 6.7% from 3Q 2024). Net income: CN¥24.2m (up 42% from 3Q 2024). Profit margin: 23% (up from 15% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Chison Medical Technologies Co., Ltd. to Report Q3, 2025 Results on Oct 20, 2025 Chison Medical Technologies Co., Ltd. announced that they will report Q3, 2025 results on Oct 20, 2025 Declared Dividend • Jul 11
Dividend increased to CN¥1.00 Dividend of CN¥1.00 is 25% higher than last year. Ex-date: 15th July 2025 Payment date: 15th July 2025 Dividend yield will be 3.3%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (82% earnings payout ratio) and cash flows (88% cash payout ratio). The dividend has increased by an average of 7.0% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 30
Chison Medical Technologies Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Chison Medical Technologies Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Board Change • Jun 19
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Shanjue Mo is the most experienced director on the board, commencing their role in 1996. Independent Director Shouxi Li was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.37 (vs CN¥0.41 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.37 (down from CN¥0.41 in 1Q 2024). Revenue: CN¥127.7m (down 9.2% from 1Q 2024). Net income: CN¥41.6m (down 8.6% from 1Q 2024). Profit margin: 33% (in line with 1Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • Apr 25
Chison Medical Technologies Co., Ltd., Annual General Meeting, May 16, 2025 Chison Medical Technologies Co., Ltd., Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Wuxi, Jiangsu China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥26.06, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 20x in the Medical Equipment industry in China. Total returns to shareholders of 11% over the past three years. New Risk • Apr 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Dividend is not well covered by cash flows (100% cash payout ratio). Announcement • Mar 28
Chison Medical Technologies Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Chison Medical Technologies Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Reported Earnings • Mar 02
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥1.28 (down from CN¥1.33 in FY 2023). Revenue: CN¥468.8m (down 3.1% from FY 2023). Net income: CN¥143.4m (down 2.1% from FY 2023). Profit margin: 31% (in line with FY 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 5% per year. New Risk • Feb 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (100% cash payout ratio). Share price has been volatile over the past 3 months (9.1% average weekly change). Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥30.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 20x in the Medical Equipment industry in China. Total returns to shareholders of 13% over the past three years. Announcement • Dec 27
Chison Medical Technologies Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Chison Medical Technologies Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.26 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.15 (down from CN¥0.26 in 3Q 2023). Revenue: CN¥114.7m (up 8.8% from 3Q 2023). Net income: CN¥17.1m (down 42% from 3Q 2023). Profit margin: 15% (down from 28% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥23.29, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 23% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (119% cash payout ratio). Share price has been volatile over the past 3 months (7.3% average weekly change). Announcement • Sep 30
Chison Medical Technologies Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Chison Medical Technologies Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥22.95, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 22% over the past three years. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.53 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.32 (down from CN¥0.53 in 2Q 2023). Revenue: CN¥107.0m (down 19% from 2Q 2023). Net income: CN¥35.8m (down 40% from 2Q 2023). Profit margin: 34% (down from 45% in 2Q 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Chison Medical Technologies Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Chison Medical Technologies Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Reported Earnings • Apr 20
First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.47 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.41 (down from CN¥0.47 in 1Q 2023). Revenue: CN¥140.6m (down 15% from 1Q 2023). Net income: CN¥45.5m (down 13% from 1Q 2023). Profit margin: 32% (in line with 1Q 2023). Revenue is forecast to grow 41% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Apr 20
Chison Medical Technologies Co., Ltd., Annual General Meeting, May 10, 2024 Chison Medical Technologies Co., Ltd., Annual General Meeting, May 10, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Wuxi, Jiangsu China Buy Or Sell Opportunity • Apr 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to CN¥29.88. The fair value is estimated to be CN¥37.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 108% in 2 years. Earnings are forecast to grow by 93% in the next 2 years. Announcement • Mar 30
Chison Medical Technologies Co., Ltd. to Report Q1, 2024 Results on Apr 19, 2024 Chison Medical Technologies Co., Ltd. announced that they will report Q1, 2024 results on Apr 19, 2024 Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥37.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Medical Equipment industry in China. Total returns to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥38.00 per share. Buy Or Sell Opportunity • Feb 28
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 33% to CN¥29.08. The fair value is estimated to be CN¥37.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 108% in 2 years. Earnings are forecast to grow by 93% in the next 2 years. Reported Earnings • Feb 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥1.41 (up from CN¥0.94 in FY 2022). Revenue: CN¥490.0m (up 29% from FY 2022). Net income: CN¥155.1m (up 47% from FY 2022). Profit margin: 32% (up from 28% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Feb 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Dividend is not well covered by cash flows (165% cash payout ratio). Share price has been volatile over the past 3 months (8.3% average weekly change). Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥24.14, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥34.86 per share. Buy Or Sell Opportunity • Jan 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 30% to CN¥27.86. The fair value is estimated to be CN¥34.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years. Earnings per share has grown by 8.7%. Revenue is forecast to grow by 125% in 2 years. Earnings are forecast to grow by 133% in the next 2 years. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥41.00, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 8.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥40.10 per share. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.44 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.26 (down from CN¥0.44 in 3Q 2022). Revenue: CN¥105.4m (down 16% from 3Q 2022). Net income: CN¥29.5m (down 41% from 3Q 2022). Profit margin: 28% (down from 40% in 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Oct 10
Chison Medical Technologies Co., Ltd. (SHSE:688358) commences an Equity Buyback for CNY 20 million worth of its shares, under the authorization approved on September 12, 2023. Chison Medical Technologies Co., Ltd. (SHSE:688358) commences share repurchases on September 28, 2023, under the program mandated by the shareholders in the Extraordinary General Meeting held on September 12, 2023. As per the mandate, the company is authorized to repurchase its A shares for a total of CNY 20 million. The shares will be purchased at a price not exceeding CNY 62.05 per share. The repurchased shares will be used for the implementation of ESOP or equity incentive plan. The program will be funded from company's own funds. The program will be valid for 12 months from the date of the shareholder's meeting. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.53 (vs CN¥0.46 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.53 (up from CN¥0.46 in 2Q 2022). Revenue: CN¥131.2m (up 2.6% from 2Q 2022). Net income: CN¥59.5m (up 17% from 2Q 2022). Profit margin: 45% (up from 40% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Chison Medical Technologies Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Chison Medical Technologies Co., Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥60.02, the stock trades at a trailing P/E ratio of 50.4x. Average trailing P/E is 35x in the Medical Equipment industry in China. Total returns to shareholders of 7.7% over the past three years. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥62.44, the stock trades at a trailing P/E ratio of 52.4x. Average trailing P/E is 35x in the Medical Equipment industry in China. Total returns to shareholders of 9.5% over the past three years. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to CN¥55.13, the stock trades at a trailing P/E ratio of 46.3x. Average trailing P/E is 35x in the Medical Equipment industry in China. Total returns to shareholders of 13% over the past three years. Reported Earnings • Apr 20
First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.22 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.47 (up from CN¥0.22 in 1Q 2022). Revenue: CN¥165.2m (up 65% from 1Q 2022). Net income: CN¥52.5m (up 111% from 1Q 2022). Profit margin: 32% (up from 25% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.27 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.44 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥125.8m (up 24% from 3Q 2021). Net income: CN¥49.9m (up 63% from 3Q 2021). Profit margin: 40% (up from 30% in 3Q 2021). Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥45.11, the stock trades at a trailing P/E ratio of 35.8x. Average trailing P/E is 31x in the Medical Equipment industry in China. Total returns to shareholders of 42% over the past year. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥37.19, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 30x in the Medical Equipment industry in China. Total returns to shareholders of 13% over the past year. Reported Earnings • Aug 21
Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.46 (up from CN¥0.22 in 2Q 2021). Revenue: CN¥128.0m (up 22% from 2Q 2021). Net income: CN¥50.9m (up 109% from 2Q 2021). Profit margin: 40% (up from 23% in 2Q 2021). Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥31.58, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 32x in the Medical Equipment industry in China. Total loss to shareholders of 8.7% over the past year. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment deteriorated over the past week After last week's 30% share price decline to CN¥25.18, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 32x in the Medical Equipment industry in China. Total loss to shareholders of 52% over the past year. Reported Earnings • Apr 19
First quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.28 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.31 (up from CN¥0.28 in 1Q 2021). Revenue: CN¥100.4m (up 23% from 1Q 2021). Net income: CN¥24.9m (up 9.1% from 1Q 2021). Profit margin: 25% (down from 28% in 1Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Mar 04
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥1.50 (up from CN¥1.25 in FY 2020). Revenue: CN¥406.7m (up 22% from FY 2020). Net income: CN¥119.8m (up 20% from FY 2020). Profit margin: 30% (in line with FY 2020). Revenue was in line with analyst estimates. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.33 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥101.9m (up 15% from 3Q 2020). Net income: CN¥30.6m (up 15% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Reported Earnings • Aug 15
Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.27 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥105.2m (up 67% from 2Q 2020). Net income: CN¥24.4m (up 12% from 2Q 2020). Profit margin: 23% (down from 35% in 2Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.22 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥81.6m (up 22% from 1Q 2020). Net income: CN¥22.8m (up 31% from 1Q 2020). Profit margin: 28% (up from 26% in 1Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥1.32 (vs CN¥1.70 in FY 2019) The company reported a mediocre full year result with weaker revenues, although earnings were flat and profit margins improved. Full year 2020 results: Revenue: CN¥342.2m (down 7.4% from FY 2019). Net income: CN¥106.0m (flat on FY 2019). Profit margin: 31% (up from 28% in FY 2019). The increase in margin was driven by lower expenses. Is New 90 Day High Low • Jan 06
New 90-day low: CN¥49.00 The company is down 14% from its price of CN¥56.92 on 30 September 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 6.0% over the same period. Is New 90 Day High Low • Dec 12
New 90-day low: CN¥54.52 The company is down 2.0% from its price of CN¥55.87 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period. Announcement • Jul 17
Chison Medical Technologies Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020 Chison Medical Technologies Co., Ltd. announced that they will report first half, 2020 results on Aug 29, 2020 
